Editorials |
From the Department of Cell Biology and Molecular Medicine, Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark.
Correspondence to Junichi Sadoshima, MD, PhD, Cardiovascular Research Institute, UMDNJ–Newark, 185 S Orange Ave, MSB G609, Newark, NJ 07103. E-mail sadoshju@umdnj.edu
See related article, pages 983–991
Key Words: glycogen synthase kinase-3 cardioprotection mitochondria metabolic adaptation ATP
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
A prolonged period of ischemia leads to death of cardiac myocyte (myocardial infarction). In theory, quicker restoration of blood supply to the ischemic myocardium should reduce the extent of myocardial injury. However, reperfusion itself has the potential to exacerbate myocardial damage, a phenomenon known as reperfusion injury. Mitochondrial dysfunction plays a central role in mediating myocardial cell death by ischemia/reperfusion (IR). In particular, opening of the mitochondria permeability transition pore (mPTP) has been attributed to irreversible cell damage.1,2 Studies on the effects of preconditioning and postconditioning have revealed a number of signaling cascades that afford cardioprotection involving the mitochondria. Among them, inhibition of glycogen synthase kinase (GSK)-3 has been causatively related by many investigators to the protective effects of ischemic preconditioning,3,4 pharmacological preconditioning,5 anesthetic postconditioning,6 ischemic postconditioning,7 and many chemical cardioprotective interventions.8–13 However, some controversies exist regarding the involvement of GSK-3 inhibition in the ischemic preconditioning and postconditioning effects observed in mice.14
GSK-3 is a serine/threonine kinase, the activity of which is inhibited by phosphorylation induced by activation of upstream kinases. The activity of GSK-3β is decreased by ischemia because of phosphorylation of serine 9 through a phosphatidylinositol 3-kinase–dependent mechanism.4 Inhibition of GSK-3 during IR appears to be an important mechanism of myocardial adaptation because a number of cardioprotective agents use inhibition (phosphorylation) of mitochondrial GSK-3β as the common downstream target.15 We speculate that GSK-3 inhibitors either mimic preconditioning or ensure greater levels of GSK-3 inhibition during IR. However, an important question remains: How does GSK-3 inhibition achieve cardioprotection against
Related Article:
Circ. Res. 2008 103: 983-991.
This article has been cited by other articles:
![]() |
K. R. Chaudhary, S. N. Batchu, D. Das, M. R. Suresh, J. R. Falck, J. P. Graves, D. C. Zeldin, and J. M. Seubert Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function Cardiovasc Res, July 15, 2009; 83(2): 362 - 370. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |